Latest Breaking News On - Bloomberg gilead sciences inc - Page 1 : comparemela.com

(Bloomberg) Gilead Sciences Inc.’s Trodelvy failed to significantly improve survival in a trial of patients with advanced lung cancer, a blow to the targeted treatment that’s in one of the most promising classes in oncology.Most Read from BloombergFlorida Governor DeSantis Drops Out of 2024 Race, Endorses TrumpHong Kong Stocks at 36% Discount Show True Depth of China GloomMorgan Stanley, JPMorgan Say Buy the Dip After Treasury RoutGloom Over China Assets Is Spreading Beyond Battered StocksHed

City ofUnited kingdomUnited statesNew yorkFoster cityMerdad parseyDaiichi sankyoBloomberg businessweekMerck coDaiichi sankyo coAbbvie incImmunogen incAmbrx biopharma incAstrazeneca plcBloomberg gilead sciences incMedical officer merdad parsey